Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies

Assessment of combination therapy in BALB/c mice injected with carbapenem-resistant Enterobacteriaceae strains. Frontiers in Microbiology 6: 999-999, 2015

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clinic Proceedings 86(3): 250-259, 2011

Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions. European Journal of Clinical Microbiology & Infectious Diseases 34(12): 2307-2311, 2016

Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Review of Anti-Infective Therapy 15(6): 519-526, 2017

Treatment of Hospital or Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Enterobacteriaceae: Leveraging Molecular Resistance Testing and Combination Therapy to Improve Outcomes. Clinical Infectious Diseases 63(10): 1395-1396, 2016

Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: A retrospective observational study. Indian Journal of Cancer 53(4): 592-594, 2017

Monotherapy versus Combination Therapy against Nonbacteremic Carbapenem-resistant Gram-negative Infections: A Retrospective Observational Study. Indian Journal of Critical Care Medicine 21(12): 825-829, 2018

Can carbapenem-resistant enterobacteriaceae susceptibility results obtained from surveillance cultures predict the susceptibility of a clinical carbapenem-resistant enterobacteriaceae?. American Journal of Infection Control 44(8): 953-955, 2016

The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients. American Journal of Infection Control 41(2): 180-182, 2013

Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. Plos One 12(10): E0186195-E0186195, 2017

Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand. Plos One 10(9): E0139116-E0139116, 2016

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections. European Journal of Clinical Microbiology & Infectious Diseases, 2017

Changing epidemiology of carbapenem-resistant Enterobacteriaceae carriage during an outbreak of carbapenem-resistant Klebsiella pneumoniae. Journal of Hospital Infection 76(4): 355-356, 2011

In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. Journal of Global Antimicrobial Resistance 3(4): 278-282, 2016

In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 58(6): 3541-3546, 2014